All Episodes
ReachMD CME — 404 episodes
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
Target Locked in gMG: Why T2T Matters
Minimal By Design: Define MSE Endpoints
Turning Flares Into Function: Flag Uncontrolled Disease
When to Begin FcRn: Initiation Criteria, Key Evidence
The IgG Clock: Redose Using IgG Kinetics
Escalate With Intention: Stepwise, Target-Anchored Moves
Shared Goals, Shared Gains: Align With Patient Preferences
The 2-Point Signal: Apply ≥2-Point Rule
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
APRIL Uncovered: An Upstream Driver in IgAN
Mechanism-Based Targeting: Why APRIL Matters in IgAN
IgAN SOC: Strengths and Limits
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Emerging Evidence: IgAN Disease-Modifying Agents
Emerging Therapies in IgAN: Who Could Benefit the Most?
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
The Struggle Is Real
TKI: The New TKO for Retinal Diseases
To Implant or to Inject?
Who Needs a TKI? Identifying the Right Candidates
So You Think You Want a TKI?
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
Do Not Delay: Timing, Triggers, and Identifying the Right Patient for Additional Therapies in HFrEF
Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
Test Your Skills and Learn From Experts on Best Practice in Diagnosis and Management of Systemic Mastocytosis
Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
Double-Class Refractory CLL in Community Practice: Current and Future Management
Personalizing First-Line Therapy for CLL
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
RAS Across Tumors: Who to Test When
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
From Pixels to Practice: Advancing HCM Care With Multimodality Imaging
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Interdisciplinary Strategies for BRCA-Mutated EBC: Testing, Targeting, and Team-Based Care
Oh, the Hats You'll Wear! The Many Modalities of Pediatric Obesity Management
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
Addressing Unmet Needs in Metastatic Uveal Melanoma
Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
Practical Perspectives in Myasthenia Gravis # 1: Diagnostic Logistics—Navigating Complexity Across Ages
Practical Perspectives in Myasthenia Gravis #2: Patient Stratification and Antibody Profiling—Personalizing the Disease Lens
Practical Perspectives in Myasthenia Gravis #3: Therapeutic Selection and Monitoring Efficacy—Matching Mechanisms to Patients
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?
Severity Assessment: Can You Pin the Stage on the Patient?
IBD Immunopathogenesis: Do You Know What You're Blocking?
Tailoring Treatment: Can You Select the Best Therapy?
Case Review: Can You Crack This IBD Case?
Treat-to-Target: Are We There Yet?
Remission: Can You Prove It?
Switching Strategies: Switch or Stay—What’s Your Call?
Case Review: Targets Are Met—Can You Stick the Landing?
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
Decoding EGPA: A Clinical Deep Dive Into Diagnosis and Treatment
When Topicals Fail: The New IPC Consensus Every Clinician Should Know
New Pathways in the Treatment of DMD
Nephrology at the Helm—Advancing Timely CKD Care Through Cross-Specialty Collaboration
Optimizing Multidisciplinary Approaches in the Guideline-Driven Management of Cervical and Endometrial Cancers
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
All Sides of the Joint: Integrated TGCT Care Across Specialties
Are You On Top of Pediatric Atopic Dermatitis? Expert Guidance for Leveraging the Latest Advances in Systemic Therapy
Hepatic Encephalopathy: More Common Than You Think
Minimal Hepatic Encephalopathy: Hiding in Plain Sight?
Minimal Hepatic Encephalopathy: A Covert Operation?
The Slippery Slope of Overt Hepatic Encephalopathy
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
Treatment of Hepatic Encephalopathy: Primary vs Secondary Prophylaxis
Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy
Current Treatment of Hepatic Encephalopathy: Is It Meeting Our Patients' Needs?
Advances in the Treatment of Overt Hepatic Encephalopathy: What's in the Pipeline?
Advances in Treatment of Hypoparathyroidism: Importance of Genetic Testing for Autosomal Dominant Hypocalcemia Type 1
Taking Action Against RSV: No Child Unprotected
Early Action in Obesity: Transforming Practice, Improving Outcomes
Rethinking Schizophrenia Treatment Through Muscarinic Modulation
Future mCRC Directions: Enhancing Anti-EGFR Therapy With Novel Combination Strategies
Future-Proofing in HAE: Advances in Long-term Prophylaxis to Prevent Attacks and Improve Quality of Life
A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies
IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
The Fifth Pillar? Closing the Gap in HFrEF
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MOA: CDH6-Targeted Antibody-Drug Conjugates
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
Updates in Major Depressive Disorder with Insomnia
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Interdisciplinary Management of Gynecologic Cancers
Screening for Cervical Cancer
Evidence- and Guideline-Based Treatment for Advanced/Metastatic Cervical Cancer
Role of Predictive Biomarkers in Endometrial Cancer
Evidence Base for First-Line Treatment Strategies for Endometrial Cancer and Delivering Guideline-Concordant Care
Evidence Base for Treatment Strategies for Endometrial Cancer After Disease Progression and Interdisciplinary Collaboration
Managing Immune-Related Adverse Events in Cervical and Endometrial Cancer
Applications in Multidisciplinary Care for Cervical Cancer
Case Applications in Multidisciplinary Care for Endometrial Cancer
Breaking the Cycle: Prioritizing Weight Loss to Improve OSA Management
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CKD-aP: Beyond the Surface
Quantifying CKD-aP: Tools for Better Care
CKD-aP or Something Else? Decoding the Diagnosis
CKD-aP Treatment Tool Kit
Elevating CKD-aP Care: New Frontier
Is CKD-aP Hiding in Your Dialysis Center?
Kappa-Opioid Settings: Real-World Evidence Insights
Improving Sleep and Mental Health in Patients with CKD-aP
The Patient-Clinician Connection in Managing CKD-aP
Not Just a Headache: Migraine Across Women’s Lifespan
Hepatic Encephalopathy: An Ominous Sign
The Clinical Spectrum of Hepatic Encephalopathy
Hepatic Encephalopathy: Tipping the Balance
You Can’t Diagnose MHE Unless You Diagnose Cirrhosis
Diagnosing Minimal Hepatic Encephalopathy: There's an App for That?
Hepatic Encephalopathy: What's Sarcopenia Got to Do With It?
Treatment of Overt Hepatic Encephalopathy
Hepatic Encephalopathy: Unmet Therapeutic Needs
Advances in the Treatment of Hepatic Encephalopathy
Global Perspectives on New Data in Type 2 Diabetes — Congress-to-Clinic Insights From ADA and EASD 2025
Primary Biliary Cholangitis: Shining Light on an "Invisible" Female Health Burden
ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive Years
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Diagnosing and Treating IBS: It Begins With One Simple Question
Women’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages
Understanding Endocrine Resistance in HR+/HER2- mBC
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
Case in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC
PI3K Pathway Inhibitors: Safety and Tolerability Profiles
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
From Resistance to Response: Evolving Strategies in MDD Management
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
The Critical Interplay: CKD, HF, and HyperkaleAmia
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Potassium Binders in Practice: Clinical Trial Evidence
Potassium Binders: Safety Comes First!
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Future Directions in Managing Hyperkalemia in CKD and HF
FSGS: When Solutions Fall Short
Current FSGS Treatment Landscape: More Questions Than Answers
FSGS: Interpretation of Proteinuria Reduction Thresholds
Emerging Therapies in Managing Adult and Pediatric Patients With FSGS: Latest Data
Monitoring FSGS: Traditional and Novel Biomarkers
DEARA Versus SOC in FSGS Management: Clinical Trial Insights
Treatment Considerations for Pediatric Patients With FSGS
Integrating the Patient Voice in FSGS Management
Future Directions in FSGS Care
Bronchiectasis Update: Diagnostic Innovations and Therapeutic Frontiers
Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma
Clinical and Safety Outcomes from the LIGHTSITE III Trial
Anatomical Outcomes from the LIGHTSITE III Trial
Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration
Best Practices for Optimized Photobiomodulation Treatment Effect: Candidate Selection
Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice
Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape
Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications
Psoriasis and Obesity: Going Pound for Pound on Comprehensive, Patient-Centered Management
Collaborative Care for CRSwNP Expert and Patient Insights
Insights and Updates: New Data on Next-Generation Retinal Treatments
Retina Case Review: Translating the Data Into Care
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
The Clinical Weight of TTR: What the Latest Data Reveal
Optimizing IgAN Care: Achieving Lower Proteinuria Targets with Combination Therapy
Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy
The Evolving Landscape of Resectable Locally Advanced HNSCC
Rationale for Combining Radiation and Immunotherapy in Resectable Locally Advanced HNSCC
Emerging Evidence for Perioperative ICIs in Locally Advanced HNSCC
Risk Stratification and Patient Selection for Perioperative ICIs
Applying Perioperative ICIs in Clinical Practice
Managing Immune-Related Adverse Events in the Perioperative Setting
Multidisciplinary Collaboration Facilitates Multimodality Therapy
Risk Reduction with GLP-1 RAs in Individuals with ASCVD and T2D: 2025 Update
Why CELMoDs Matter in Myeloma
Molecular Magic: Decoding the Unique Mechanism of CELMoDs
Data Dive: Clinical Evidence Behind CELMoDs
Precision Targeting: Matching CELMoDs to the Right Patient With Myeloma
Mastering the Sequence: CELMoDs Across Treatment Lines
Safety First: Navigating CELMoD-Associated Toxicities
Real-World Ready: Practical Tips for Community Oncologists
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
Continuity in Care: Strategies for Managing Growth Hormone Deficiency Through Life’s Stages
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Applications of Emerging Data in Resectable NSCLC
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
HER2-Driven Strategies in Metastatic NSCLC
MET and Other Emerging Targets in Metastatic NSCLC
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Stratifying Risk to Guide Therapy in R/R AML
Molecular Profiling as a Cornerstone of Precision AML Therapy
Menin Inhibitors: Biologic and Clinical Rationale
Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
Managing Adverse Events Associated With Menin Inhibitors
Applying Evidence to Clinical Practice
Emerging Directions in Menin-Directed AML Therapy
Ongoing Clinical Trials in AML With Menin Inhibitors
Expert Recommendations and Key Takeaways
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
The Latest Patient-Centered Recommendations From the 7th World Symposium on PH
Managing Travel With PAH: Logistics, Medications, Oxygen, and Emergency Preparedness
Aligning PAH Treatment Plans With Key Care Goals and Your Patients’ Priorities
Integrating Palliative Care in Pulmonary Hypertension
Patient-Reported Outcome Measures (PROMs): Valuable Insights Into the Lived Experience of PAH
A Comparison of PROMs and How to Use Them in Clinical Practice for PAH
What Challenges and Triumphs Do Patients Face While Living With PAH?
PROMs in Clinical Practice: Impacting Treatment Decisions
PROMs: Role in Clinical Research and Contributions to PAH Patient Perspectives
How Do Patient Experiences and PAH Perspectives Vary Across Regions and Cultures Worldwide?
Treatment of a Broader Population of Patients With DMD
Chairperson’s Perspective: Precision in Practice: Advancing EGFR-Altered Metastatic NSCLC Through Guideline-Concordant, Case-Based Learning
Differentiating Neuromodulation Therapies: VNS, DBS, ECT, TMS
Epilepsy: Beyond Seizure Impact
VNS: Beyond Seizure Control
QoL Matters: Brain Stem Stimulation in Patients With Unipolar Depression
Optimizing VNS Parameters: Keys to Therapeutic Success
Stemming the Tide on MASLD/MASH: It Starts on the Frontlines in Endocrinology and Primary Care Clinics
Pulmonary Hypertension: Getting the Right Diagnosis and Knowing When to Refer
New and Emerging PAH Therapies and Approaches: A Mixture of Hope and Complexity
PH Management in Unique Patients and Conditions
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Integrating IV Iron into Cancer Care: An Expert Overview of Best Practices
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
When and Why to Use CAC Scoring
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Bridging ASCVD Care Between Academic and Rural Settings
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
FSGS in Practice: Patient-Centered Decision-Making
Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs
FCS: Enhancing the Diagnosis
Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
APOC3 Inhibition: A Novel Approach to Lowering TGs
Latest Clinical Trial Outcomes and Breakthroughs for FCS
SHTG: Defining the Unmet Clinical Need
SHTG: Decoding the Latest Clinical Trial Outcomes
Remnant Cholesterol: The Missing Link in ASCVD risk
Targeting Mixed Hyperlipidemia with APOC3 Inhibition
The Road Ahead: What's on the Horizon for FCS and SHTG Management
Obesity: Unmasking the Chronic Disease Beneath the Weight
Obesity and Comorbidities: Strategies for Effective Patient Management
Treating Obesity: Lifelong Strategies from Lifestyle to Pharmacotherapy and Surgery Treating Obesity: Lifelong Strategies fFrom Lifestyle to Pharmacotherapy and Surgery
Beyond the Scale: How to Tackle Obesity’s Comorbidities
Practical Tips for GLP-1 RA Therapy Success
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Advancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs
New Frontiers in the Treatment of DMD Across the Age Spectrum
Insights from Experts: Preventing and Managing CMV Post-Solid Organ Transplant
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
An Overview of Current and Emerging Treatment Options for Hemophilia A & B
The Impact of Hemophilia Across Patients’ Lives
Evaluating Novel Factor Replacement Strategies: Extended and Ultra-Half-Life Factors and Factor Mimetics
Evaluating Emerging Treatment Options: Rebalancing Therapies
The Promise and Future of Gene Therapy
Considering the Promise of New and Emerging Treatments for Hemophilia: The Need for ITI?
Considering the Promise of New and Emerging Treatments for Hemophilia: Managing Thrombotic Risks
Integrating New Therapies Into Healthcare
Multidisciplinary Team Collaboration in the New Era of Hemophilia Treatment
Moving Forward–What Is on the Horizon? Personalized Therapies for Patients
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
Recent Updates in HER2-Targeted TKIs for Metastatic Breast Cancer
Emerging Data in HER2-Targeted ADCs for Metastatic Breast Cancer
Applying Data Into Practice: Sequencing Strategies for HER2-Targeted Breast Cancer
The Alloimmune Disorders of Pregnancy
Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): The Platelet Equivalent of Rh Disease
Classification/Suspecting a Diagnosis of FNAIT/NAIT
Current Diagnostic Signs, Symptoms, and Lab Tests for FNAIT
Current Management Strategies for FNAIT
Managing the “Next Pregnancy” in Patients With an FNAIT-Affected First Child
Screening for FNAIT: Anticipating HPA-1a Incompatibility
Neonatal FcRn Inhibition: A New Pathway for Addressing the Alloimmune Disorders of Pregnancy
Nipocalimab: An FcRn Inhibitor and Its Role in Treating HDFN
Key Patient Counseling Issues Surrounding FNAIT and Its Risk in Subsequent Pregnancies
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
The Integral Role of GnRH Antagonists in the Management of Endometriosis
Pre- and Postoperative Use of GnRH Antagonists
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment
Chairperson’s Perspective: CDK 4/6 Inhibitors: Practice-Changing Implications of Targeted Therapies in HR+/HER2- Breast Cancer
Gout Beyond the Joints: What’s the Hidden Danger?
Is Gout Hiding in the Nephrology Clinic?
Is Managing Gout in the Nephrology Clinic a Challenge?
Center of the Target: Which Patients Are Most Likely to Develop Gout?
Treat or Refer: Who Is Responsible for Managing Gout?
Can You Manage Patients With Uncontrolled Gout More Effectively?
What’s New About Gout? Nephrology Perspective
What’s New About Gout? Rheumatology Perspective
What Are the Emerging Therapies for Managing Gout?
Should We Look for Gout in the Cardiology Clinic?
Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 4: Emerging Therapies
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 3: Management
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 2: Progression and Prognostication
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 1: Detection and Diagnosis
The Clinical Significance of Imaging in the Management of ADPKD
Expert Answers to Common Questions for the Management of Hemophilia A